Q2 2026 IDEXX Laboratories Inc Earnings Call Transcript
Key Points
- IDEXX Laboratories Inc (IDXX) delivered excellent Q2 2026 results with 10% reported and 9% organic revenue growth, driven by over 10% organic growth in CAG Diagnostics recurring revenues.
- Strong innovation momentum with inVue Dx placements on track for full-year goal of 5,500 units, and the successful rollout of FNA and Cancer Dx panel expansion, which is expected to drive future growth.
- Comparable operating margin expanded by 110 basis points in Q2, supported by gross margin gains from strong recurring revenue growth and favorable product costs.
- International CAG Diagnostics recurring revenues grew nearly 12% organically, sustaining double-digit gains and reflecting successful commercial execution and market expansion.
- The company raised its full-year 2026 revenue and EPS guidance, reflecting confidence in continued strong performance and upcoming product launches.
- High customer retention rates (high 90s) and a growing installed base (up 11% year-over-year) provide a durable foundation for future recurring revenue growth.
- US same-store clinical visits declined 1.3% in Q2, with continued pressure on wellness visits, which remain a headwind to overall growth.
- CAG Diagnostic instrument revenues declined 20% organically in Q2 due to lapping the broad commercial availability of inVue Dx in the prior year.
- The company faces a $15 million headwind from updated foreign currency effects, which negatively impacts reported revenue and EPS for the full year.
- Inflationary cost pressures, though easing, continue to impact the business, and the company expects to increase operating expenses in the second half for investments.
- The second half of 2026 is expected to see modest operating margin expansion (20-50 basis points in Q3), reflecting increased investments in commercial and R&D initiatives.
- US same-store clinical visits are expected to decline approximately 1.5% in the second half, indicating persistent softness in the veterinary visit environment.
Good morning, and welcome to the IDEXX Laboratories second-quarter 2026 earnings conference call. As a reminder, today's conference is being recorded. Participating in the call this morning are Mike Erickson, President and Chief Executive Officer; Andrew Emerson, Chief Financial Officer; and John Ravis, Vice President, Investor Relations.
IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.
Additional information regarding these risks and uncertainties is available under the forward-looking statements notice in our press release issued this morning as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx.com.
During this call, we will be discussing certain financial measures not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
